These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

989 related articles for article (PubMed ID: 19412164)

  • 41. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
    Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
    Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
    Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
    Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
    Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
    Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.
    Song Z; Wei W; Xiao W; Al-Saleem ED; Nejati R; Chen L; Yin J; Fabrizio J; Petrus MN; Waldmann TA; Yang Y
    Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28980-28991. PubMed ID: 33139544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease.
    Zhou Q; Wang H; Schwartz DM; Stoffels M; Park YH; Zhang Y; Yang D; Demirkaya E; Takeuchi M; Tsai WL; Lyons JJ; Yu X; Ouyang C; Chen C; Chin DT; Zaal K; Chandrasekharappa SC; Hanson EP; Yu Z; Mullikin JC; Hasni SA; Wertz IE; Ombrello AK; Stone DL; Hoffmann P; Jones A; Barham BK; Leavis HL; van Royen-Kerkof A; Sibley C; Batu ED; Gül A; Siegel RM; Boehm M; Milner JD; Ozen S; Gadina M; Chae J; Laxer RM; Kastner DL; Aksentijevich I
    Nat Genet; 2016 Jan; 48(1):67-73. PubMed ID: 26642243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN.
    Heyninck K; De Valck D; Vanden Berghe W; Van Criekinge W; Contreras R; Fiers W; Haegeman G; Beyaert R
    J Cell Biol; 1999 Jun; 145(7):1471-82. PubMed ID: 10385526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma.
    Cai N; Chen Z; Huang Y; Shao S; Yu H; Wang Y; He S
    Cancer Biol Ther; 2020; 21(3):241-247. PubMed ID: 31731887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma.
    Chung GT; Lou WP; Chow C; To KF; Choy KW; Leung AW; Tong CY; Yuen JW; Ko CW; Yip TT; Busson P; Lo KW
    J Pathol; 2013 Nov; 231(3):311-22. PubMed ID: 23868181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
    Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20.
    Sisto M; Barca A; Lofrumento DD; Lisi S
    Clin Exp Immunol; 2016 May; 184(2):183-96. PubMed ID: 26724675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Zhang B
    Semin Cancer Biol; 2016 Aug; 39():26-31. PubMed ID: 27546290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.